Physician profile
Michael J Schied
NPI 1750478228
$592.75
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $52.71 · 2021: $185 · 2022: $56.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $200.85 | 2019-2022 | |
| Abbvie INC. | $106.16 | 2019-2021 | |
| Myovant Sciences INC. | $46.01 | 2021 | |
| Roche Diagnostics Corporation | $45.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.89 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $39.19 | 2019 | |
| Merck Sharp & Dohme LLC | $37.84 | 2019-2020 | |
| Aspira Women'S Health INC | $32.63 | 2022 | |
| Coopersurgical, INC. | $26.35 | 2021 | |
| Therapeuticsmd, INC. | $13.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schied listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.